2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Serologic Tests, Bioinformatics, Clinical Procedures, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, CHIP, Genomics, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4067 Mass spectrometry assay to quantify soluble B-cell maturation antigen in serum of patients with multiple myeloma

Mariya Liyasova, PhD, Teresa Nunez de Villavicencio Diaz, PhD2, Xin Xu3, Kyle Suttill4, Chelsea Reitzel5, Abir Khaled, PhD6, Michael J. Slade, MD, MSCI7, Julie Fortier, PhD8, Thierry Le Bihan, PhD9, Liqiang Yang, PhD10, Bin Ma, PhD11
1 Rapid Novor, Kitchener, Ontario, Canada
2 Rapid Novor, Kitchener, Ontario, Canada
3 Rapid Novor, Kitchener, Ontario, Canada
4 Rapid Novor, Kitchener, Ontario, Canada
5 Rapid Novor, Kitchener, Ontario, Canada
6 Rapid Novor, Kitchener, Ontario, Canada
7 Washington University, St. Louis, Missouri, United States
8 Washington University, St. Louis, Missouri, United States
9 Rapid Novor, Kitchener, Ontario, Canada
10 Rapid Novor, Kitchener, Ontario, Canada
11 Rapid Novor, Kitchener, Ontario, Canada

Soluble B-cell maturation antigen (sBCMA), a product of γ-secretase cleavage of membrane-bound BCMA, has recently been established as a promising biomarker in multiple myeloma (MM). Soluble BCMA levels have been correlated with disease burden (including MRD), treatment response rate, and progression free survival. Thus, monitoring sBCMA can be useful in assessing treatment response in patients with nonsecretory or oligosecretory MM, when M-protein is either absent or difficult to monitor, a disease state that is commonly observed following myeloma immunotherapy. In addition, sBCMA levels can be used to understand the pharmacokinetics of BCMA-targeting therapies, as sBCMA can serve as a drug sink. Here we report a mass spectrometry (MS)-based assay to quantify sBCMA peptide with high sensitivity and specificity. Unlike commonly used ELISA assay, peptide-level MS-based assay is free from interference from the BCMA-targeting antibodies. To demonstrate the applicability of the assay, we quantified sBCMA in MM serum samples and compared the results to the gold standard sBCMA ELISA.
sBCMA assay relies on the immuno-enrichment and quantification of peptide CSSNTPPLTCQR with targeted mass spectrometry. Serum samples were reduced with DTT, alkylated with iodoacetamide and digested with trypsin. sBCMA peptide was enriched from digested serum using anti-peptide mAb developed in-house using proprietary REpAb® technology. The enriched sample was then separated by Evosep One liquid chromatography and analyzed with parallel reaction monitoring (PRM) on Orbitrap Exploris 120 mass spectrometer. sBCMA was quantified relative to control serum samples using recombinant sBCMA reduced with stable isotope-labelled iodoacetamide as an internal standard. To determine the lower limit of quantification (LLoQ) mouse serum lacking the target peptide was spiked with the increasing amounts of recombinant sBCMA. The assay demonstrated exceptional linearity from 62.5 to 4000 ng/mL of spiked sBCMA (R2=0.998) with the limit of detection (LOD) at 3.9 ng/mL. The assay only requires 10 microliters of serum or plasma without the need for diagnostic sample and can be performed at any time point, as frequently as needed.
sBCMA MS quant assay was compared to sBCMA ELISA for 27 patients newly diagnosed with MM. All patients underwent autologous stem cell transplant (ASCT) and had banked serum samples at diagnosis and day 100 post-ASCT. At the diagnosis, 15 patients presented with IgG-type M-protein, 5 patients had IgA type, while 7 patients had LC-only MM. At day 100 post-ASCT, 18 patients (67%) reached CR or sCR, 7 patients (26%) reached VGPR, while 2 patients had either PR or stable disease. The sBCMA MS quant and ELISA results were reported as a ratio to control, whereby sBCMA amount in control pooled serum was set to 1. sBCMA was detected by mass spectrometry in all patients at all time points. When MS was used of quantify sBCMA, in all but one patient ratio to control at diagnosis was higher (median 20.22, range: 0.41-605.08) than at day 100 post-ASCT (median: 0.76, range: 0.29-4.22). The data were consistent with ELISA results where at diagnosis the median sBCMA ratio was 11.01 (range: 0-118.97), while at day 100 post-ASCT the median sBCMA ratio was 0.54 (range 0.12-2.97). Strong correlation (R2=0.88) was observed between MS quant and ELISA but only for ratios to control not exceeding 35 in MS quant. At higher ratios, the correlation was poor due to lower values obtained in ELISA compared to MS quant. There was no correlation between M-protein and sBCMA levels at the time of diagnosis. Interestingly, sBCMA levels measured by MS quant were significantly higher in the diagnostic sample of IgA patients compared to IgG (p=0.001) or FLC (p=0.03) patients.
To conclude, we developed an assay to measure sBCMA with antibody-enriched peptide-level mass spectrometry. The assay demonstrated a good correlation to sBCMA ELISA in MM patients, proving its analytic validity. Quantification of sBCMA with MS opens the possibility to monitor the disease burden in MM patients regardless of the M-protein type. Clinical studies in patients treated with BCMA-targeted therapies are needed to establish the role of MS-based sBCMA assay in the patient triage, drug pharmacokinetics and disease monitoring.

Mariya Liyasova, PhD: Rapid Novor - Current Employment